Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

21. Infectious diseases in pregnancy screening (IDPS): programme overview

Infectious diseases in pregnancy screening (IDPS): programme overview Infectious diseases in pregnancy screening (IDPS): programme overview - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance and support Guidance Infectious diseases in pregnancy screening (IDPS): programme overview (...) Information on the programme, including the screening tests, commissioning, quality assurance, education and training. Published 1 January 2015 Last updated 23 June 2020 — From: Contents Public information about . Healthcare professionals, including midwives should offer and recommend screening to all pregnant women as part of their antenatal care. Screening is a choice, however the early detection and treatment offered by screening can significantly reduce the chances of a mother passing on an infection

2020 Public Health England

22. Is 45 really the new 50 in colorectal cancer screening?

Is 45 really the new 50 in colorectal cancer screening? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca June 29, 2020 (...) Is 45 really the new 50 in colorectal cancer screening? Clinical Question: Should we lower the age that average risk patients commence colorectal cancer screening from 50 to 45? Bottom Line: In developed countries, the incidence of colorectal cancer in persons under 50 years old has increased by 20-30% in the last 20 years. However, the absolute risk increase is only 1-4 per 100,000 persons. Screening average risk patients under age 50 should not be encouraged at this time. Evidence: • Population

2020 Tools for Practice

23. Prostate cancer screening with the PSA test

Prostate cancer screening with the PSA test 1 Translation of Chapters 1 to 6 of the final report S19-01 Prostatakrebsscreening mittels PSA-Test (Version 1.0; Status: 24 April 2020 [German original], 10 June 2020 [English translation]). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission (...) No. S19-01 Prostate cancer screening with a PSA test 1 Extract of final report S19-01 Version 1.0 PSA screening 24 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Prostate cancer screening with a PSA test Commissioning agency: Federal Joint Committee Commission awarded on: 18 April 2019 Internal Commission No.: S19-01 Address of publisher: Institut für Qualität und Wirtschaftlichkeit

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

24. ?Prenatal Screening for Down Syndrome, Trisomy 18, and Open Neural Tube Defect

?Prenatal Screening for Down Syndrome, Trisomy 18, and Open Neural Tube Defect Perinatal Services BC Obstetric Guideline: Prenatal Screening for Down Syndrome, Trisomy 18 and Open Neural Tube Defects Table of Contents EXECUTIVE SUMMARY ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 2 1? INTRODUCTION ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 3 SIPS, IPS, Quad, NIPT ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 3 Open Neural Tube Defects (ONTDs (...) ) ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 4 Counselling ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 4 Table 1: Summary of Prenatal Genetic Screening Tests ? ? ? ? ? ? ? ? 5 Table 2: Screening options available through the BC Prenatal Genetic Screening Program ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 6 2? MANAGEMENT ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 7 3? RESOURCES ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 10 BC Prenatal Genetic Screening Program Website

2020 British Columbia Perinatal Health Program

25. Old and New Geriatric Screening Tools in a Belgian Emergency Department: A Diagnostic Accuracy Study

Old and New Geriatric Screening Tools in a Belgian Emergency Department: A Diagnostic Accuracy Study Old and New Geriatric Screening Tools in a Belgian Emergency Department: A Diagnostic Accuracy Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center (...) Copy Actions Cite Share Permalink Copy Page navigation J Am Geriatr Soc Actions . 2020 Jul;68(7):1454-1461. doi: 10.1111/jgs.16503. Epub 2020 May 13. Old and New Geriatric Screening Tools in a Belgian Emergency Department: A Diagnostic Accuracy Study , , , , , , Affiliations Expand Affiliations 1 Department of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven, Leuven, Belgium. 2 Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium. 3

2020 EvidenceUpdates

26. Fluidigm Microfluidics Technology For Large Scale Screening For COVID-19

Fluidigm Microfluidics Technology For Large Scale Screening For COVID-19 Microfluidics technology has practical applications in the design of systems that process small scale, low volumes of fluids (typically sub-millimeter) to achieve multiplexing, automation, and high-throughput screening. Fluidigm Corporation is an innovative biotechnology tools provider that utilizes this technology to create an epigenetic test for early detection of the novel coronavirus that causes COVID-19. Fluidigm (...) microfluidics technology has the ability to rapidly screen a large number of samples, which enhance capabilities in identification and management of infected individuals, including those who are asymptomatic. 1 Based on the information poster by the company, diagnostic labs will be able to generate more than 6,000 individual test results per day with just one hour of hands-on time, representing a scale and parallel processing of assays not possible using microwell plates. 2 In particular, it enables

2020 MaHTAS Covid-19 Rapid Evidence Updates

27. Walk In Screening Booth For COVID-19

Walk In Screening Booth For COVID-19 Keeping medical professionals healthy during the COVID-19 pandemic is essential in slowing the rate of infection. Many governments and healthcare providers are finding this to be a difficult task juggling between the global shortage of personal protective equipment (PPE) supplies and the need to conduct mass screening and testing. It is therefore critical to provide a safe working environment that could limit the exposure of the frontline healthcare workers (...) to the biological hazards. Among the countries battling with COVID-19, South Korea has successfully contained the spreading of the virus due to its extensive and well-organized testing programme using latest technology to isolate infected people as well as trace and quarantine their contacts. Their drive- through testing concept has been adopted in Putrajaya Health Clinics for faster screening and testing of Covid-19. However, this strategy requires front-liners to operate in full personal protective equipment

2020 MaHTAS Covid-19 Rapid Evidence Updates

28. Screening for Anxiety in Adolescent and Adult Women: A Systematic Review for the Women's Preventive Services Initiative. (Abstract)

Screening for Anxiety in Adolescent and Adult Women: A Systematic Review for the Women's Preventive Services Initiative. Anxiety disorders are infrequently recognized during routine health care even though they are common in adolescent girls and adult women.To evaluate evidence on the effectiveness of screening for anxiety disorders in primary care in improving symptoms, function, and quality of life; harms of screening; accuracy of screening instruments; and effectiveness and harms (...) not screened; diagnostic accuracy studies of screening instruments; and systematic reviews of randomized trials of behavioral and pharmacologic treatments.Dual extraction and quality assessment of individual studies.No studies evaluated the overall effectiveness or harms of screening. Thirty-three studies and 2 systematic reviews (171 studies; 112 574 participants) evaluated the diagnostic accuracy of 27 screening instruments and their variations against a clinical diagnosis or other instruments. Most

2020 Annals of Internal Medicine

29. Screening for Anxiety in Adolescent and Adult Women: A Recommendation From the Women's Preventive Services Initiative. (Abstract)

Screening for Anxiety in Adolescent and Adult Women: A Recommendation From the Women's Preventive Services Initiative. The Women's Preventive Services Initiative (WPSI), a national coalition of women's health professional organizations and patient representatives, developed a recommendation on screening for anxiety in adolescent and adult women to improve detection; achieve earlier diagnosis and treatment; and improve health, function, and well-being. The WPSI's recommendations are intended (...) evaluating results of a systematic review of the effectiveness of screening, accuracy of screening instruments, and benefits and harms of treatments in adolescent girls and adult women. No studies directly evaluated the overall effectiveness or harms of screening for anxiety. Twenty-seven screening instruments and their variations were moderately to highly accurate in identifying anxiety (33 individual studies and 2 systematic reviews; 171 studies total). Symptoms improved and relapse rates decreased

2020 Annals of Internal Medicine

30. Screening for Unhealthy Drug Use: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Full Text available with Trip Pro

Screening for Unhealthy Drug Use: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Illicit drug use is among the most common causes of preventable morbidity and mortality in the US.To systematically review the literature on screening and interventions for drug use to inform the US Preventive Services Task Force.MEDLINE, PubMed, PsycINFO, Embase, and Cochrane Central Register of Controlled Trials through September 18, 2018; literature surveillance through (...) September 21, 2019.Test accuracy studies to detect drug misuse and randomized clinical trials of screening and interventions to reduce drug use.Critical appraisal and data abstraction by 2 reviewers and random-effects meta-analyses.Sensitivity, specificity, drug use and other health, social, and legal outcomes.Ninety-nine studies (N = 84 206) were included. Twenty-eight studies (n = 65 720) addressed drug screening accuracy. Among adults, sensitivity and specificity of screening tools for detecting

2020 JAMA

31. Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement. An estimated 12% of adults 18 years or older and 8% of adolescents aged 12 to 17 years report unhealthy use of prescription or illegal drugs in the US.To update its 2008 recommendation, the USPSTF commissioned reviews of the evidence on screening by asking questions about drug use and interventions for unhealthy drug use in adults and adolescents.This recommendation statement applies to adults 18 years (...) certainty that screening by asking questions about unhealthy drug use has moderate net benefit when services for accurate diagnosis of unhealthy drug use or drug use disorders, effective treatment, and appropriate care can be offered or referred. In adolescents, because of the lack of evidence, the USPSTF concludes that the benefits and harms of screening for unhealthy drug use are uncertain and that the balance of benefits and harms cannot be determined.The USPSTF recommends screening by asking

2020 JAMA

32. Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. (Abstract)

Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. The Patient Health Questionnaire depression module (PHQ-9) is a 9-item self-administered instrument used for detecting depression and assessing severity of depression. The Patient Health Questionnaire-2 (PHQ-2) consists of the first 2 items of the PHQ-9 (which assess the frequency of depressed mood and anhedonia) and can be used as a first step to identify (...) the clinical and research value of this combined approach to screening.

2020 JAMA

33. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review Full Text available with Trip Pro

AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review - Gastroenterology Go search This Journal Search AGA Journals , P1822-1830, May 01, 2020 Powered By Mendeley Share on AGA Clinical Practice Update on Screening and Surveillance (...) of cirrhosis, is often diagnosed at advanced stages, and is associated with lower receipt of curative therapy and with poorer survival, current society guidelines provide limited guidance/recommendations addressing HCC surveillance in patients with NAFLD outside the context of established cirrhosis. Limited data are presently available to guide clinicians with respect to which patients with NAFLD should undergo HCC surveillance, optimal screening tools, frequency of monitoring, and the influence

2020 American Gastroenterological Association Institute

34. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study

Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health (...) Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul;43(7):1553-1556. doi: 10.2337/dc19-1944. Epub 2020 Apr 28. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Endocrinology, Department of Pediatrics, The Hospital

2020 EvidenceUpdates

35. Hepatitis C Virus Infection in Adolescents and Adults: Screening

Hepatitis C Virus Infection in Adolescents and Adults: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Adults aged 18 to 79 years The USPSTF recommends screening for hepatitis C virus (HCV) infection in adults aged 18 to 79 years. B View the Clinical Summary in What does the USPSTF recommend? For adults aged 18 to 79 years: Grade B Screen adults for hepatitis C virus (HCV) infection. To whom does (...) this recommendation apply? Asymptomatic adults (including pregnant persons) aged 18 to 79 years without known liver disease. What’s new? This recommendation expands the population that should be screened. The USPSTF now recommends that all adults aged 18 to 79 years be screened. Previously, it recommended screening adults born between 1945 and 1965 and others at high risk. How to implement this recommendation? Screen. Screen adults aged 18 to 79 years with anti–HCV antibody testing followed by confirmatory

2020 U.S. Preventive Services Task Force

36. Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK

Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Considerations (...) relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK Technical report 12 Jun 2020 Cite: European Centre for Disease Prevention and Control. Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19

2020 European Centre for Disease Prevention and Control - Technical Guidance

37. Unhealthy Drug Use: Screening

Unhealthy Drug Use: Screening Recommendation: Unhealthy Drug Use: Screening | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation: Unhealthy Drug Use: Screening Recommendation: Unhealthy Drug Use: Screening Recommendation Summary Population Recommendation Adults age 18 years or older The USPSTF recommends screening by asking questions about unhealthy drug use in adults age 18 years or older. Screening should be implemented when services (...) for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. (Screening refers to asking questions about unhealthy drug use, not testing biological specimens.) B Adolescents The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for unhealthy drug use in adolescents. See the "Practice Considerations" section for suggestions for practice regarding the I statement. I Clinician Summary What does the USPSTF

2020 U.S. Preventive Services Task Force

38. Should temperature screening by thermal imaging systems be part of the policy response to curb COVID-19 transmission?

Should temperature screening by thermal imaging systems be part of the policy response to curb COVID-19 transmission? A Should temperature screening by thermal imaging systems be part of the policy response to curb Covid- 19 transmission? HIS Evidence were asked to examine whether mass screening by thermal imaging systems should feature in local and national strategies being implemented to control Covid-19 transmission. This is to support the work of Public Health Scotland and the Scottish (...) Government. A rapid review of existing guidance and current evidence was undertaken, with the findings summarised in this report. HIS Evidence Conclusion: The evidence on whether screening by thermal imaging systems is effective in controlling infectious disease transmission is weak or inconclusive at best. The most recent review suggested that screening alone or alongside a questionnaire was not effective at detecting infected persons. The evidence on implementation and impact of screening during

2020 Covid-19 Ad hoc papers

39. Fetal anomaly screening programme: standards

Fetal anomaly screening programme: standards Fetal anomaly screening programme: standards - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance and support Guidance Fetal anomaly screening programme: standards Screening standards for the NHS Fetal Anomaly Screening Programme (FASP (...) ). Published 1 January 2015 Last updated 5 June 2020 — From: Documents Ref: PHE publications gateway number: GW-369 HTML HTML Ref: PHE publications gateway number: GW-369 HTML If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details These documents present the national screening standards for the NHS Fetal Anomaly

2020 Public Health England

40. A multi-center evaluation of TECHNOSCREEN((R)) ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13

A multi-center evaluation of TECHNOSCREEN((R)) ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13 A Multi-Center Evaluation of TECHNOSCREEN ® ADAMTS-13 Activity Assay as a Screening Tool for Detecting Deficiency of ADAMTS-13 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Thromb Haemost Actions . 2020 Apr 2. doi: 10.1111/jth.14815. Online ahead of print. A Multi-Center Evaluation of TECHNOSCREEN ® ADAMTS-13 Activity Assay as a Screening Tool for Detecting Deficiency of ADAMTS-13 , , , , , , , , , , , , Affiliations Expand Affiliations 1 Diagnostic Haemostasis and Thrombosis, Viapath Analytics, Guy's & St. Thomas' Hospitals, London, UK. 2

2020 EvidenceUpdates